CN114450302A - Mhc ii类分子及其使用方法 - Google Patents

Mhc ii类分子及其使用方法 Download PDF

Info

Publication number
CN114450302A
CN114450302A CN202080067823.XA CN202080067823A CN114450302A CN 114450302 A CN114450302 A CN 114450302A CN 202080067823 A CN202080067823 A CN 202080067823A CN 114450302 A CN114450302 A CN 114450302A
Authority
CN
China
Prior art keywords
dqb
amino acid
seq
molecule
position corresponding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080067823.XA
Other languages
English (en)
Chinese (zh)
Inventor
平野直人
菅田健二
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University Health Network
Original Assignee
University Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Health Network filed Critical University Health Network
Publication of CN114450302A publication Critical patent/CN114450302A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
CN202080067823.XA 2019-07-30 2020-07-29 Mhc ii类分子及其使用方法 Pending CN114450302A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962880501P 2019-07-30 2019-07-30
US62/880,501 2019-07-30
US202063029114P 2020-05-22 2020-05-22
US63/029,114 2020-05-22
PCT/IB2020/057173 WO2021019473A1 (en) 2019-07-30 2020-07-29 Mhc class ii molecules and methods of use thereof

Publications (1)

Publication Number Publication Date
CN114450302A true CN114450302A (zh) 2022-05-06

Family

ID=74228599

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080067823.XA Pending CN114450302A (zh) 2019-07-30 2020-07-29 Mhc ii类分子及其使用方法

Country Status (12)

Country Link
US (1) US12590139B2 (https=)
EP (1) EP4004034A4 (https=)
JP (1) JP7811540B2 (https=)
KR (1) KR20220052943A (https=)
CN (1) CN114450302A (https=)
AU (1) AU2020322246A1 (https=)
BR (1) BR112022001710A2 (https=)
CA (1) CA3146292A1 (https=)
IL (1) IL290223A (https=)
MX (1) MX2022001210A (https=)
TW (1) TW202116797A (https=)
WO (1) WO2021019473A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3935175A4 (en) 2019-03-04 2023-01-04 University Health Network T-LYMPHOCYTE RECEPTORS AND METHODS OF USE THEREOF
BR112022001704A2 (pt) * 2019-07-30 2022-07-05 Univ Health Network Moléculas mhc de classe ii e métodos de uso das mesmas
CN118662607A (zh) * 2023-03-15 2024-09-20 中国科学院上海巴斯德研究所 抑制过激炎性反应的蛋白及其应用

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1244804A (zh) * 1996-11-13 2000-02-16 明治乳业株式会社 肽基免疫治疗剂
AU2002242882A1 (en) * 2001-03-27 2002-10-08 Avidex Limited Modified mhc molecules whose binding to cd8 or cd4 is inhibited and use thereof
US20030064915A1 (en) * 2001-01-24 2003-04-03 Strominger Jack L. Therapeutic peptides for demyelinating conditions
US20050042624A1 (en) * 2001-06-12 2005-02-24 Kyogo Itoh Tumor antigen
US20060084116A1 (en) * 2004-09-13 2006-04-20 Xencor, Inc. Analysis of MHC-peptide binding interactions
CN1902313A (zh) * 2003-11-05 2007-01-24 株式会社国际癌症免疫研究所 Wt1衍生的hla－dr－结合抗原肽
CN101001868A (zh) * 2004-06-17 2007-07-18 曼康公司 表位类似物
CN109476727A (zh) * 2016-04-27 2019-03-15 大学健康网络 肽-hla复合物及产生其的方法
WO2019126818A1 (en) * 2017-12-23 2019-06-27 Rubius Therapeutics, Inc. Artificial antigen presenting cells and methods of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060228758A1 (en) 2004-09-13 2006-10-12 Xencor, Inc. Analysis of MHC-peptide binding interactions
US20100099090A1 (en) 2007-03-05 2010-04-22 Bristol-Mayers Squibb Company Biomarkers and methods for determining sensitivity to ctla-4 antagonists
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2016135363A1 (es) * 2015-02-23 2016-09-01 Servicio Andaluz De Salud Método de obtención de datos útiles para predecir o pronosticar la transmisión vertical, la cronificación y/o el aclaramiento del virus de la hepatitis c
JP2018528191A (ja) 2015-08-19 2018-09-27 ラトガーズ， ザ ステイト ユニバーシティ オブ ニュー ジャージー 抗体を生成する新規な方法
BR112022001704A2 (pt) 2019-07-30 2022-07-05 Univ Health Network Moléculas mhc de classe ii e métodos de uso das mesmas
US20220291215A1 (en) 2019-07-30 2022-09-15 University Health Network Methods of identifying t cell receptors
CN114502580B (zh) 2019-07-30 2025-10-17 大学健康网络 Mhc ii类分子及其使用方法

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1244804A (zh) * 1996-11-13 2000-02-16 明治乳业株式会社 肽基免疫治疗剂
US20030064915A1 (en) * 2001-01-24 2003-04-03 Strominger Jack L. Therapeutic peptides for demyelinating conditions
AU2002242882A1 (en) * 2001-03-27 2002-10-08 Avidex Limited Modified mhc molecules whose binding to cd8 or cd4 is inhibited and use thereof
US20050042624A1 (en) * 2001-06-12 2005-02-24 Kyogo Itoh Tumor antigen
CN1902313A (zh) * 2003-11-05 2007-01-24 株式会社国际癌症免疫研究所 Wt1衍生的hla－dr－结合抗原肽
CN101001868A (zh) * 2004-06-17 2007-07-18 曼康公司 表位类似物
US20060084116A1 (en) * 2004-09-13 2006-04-20 Xencor, Inc. Analysis of MHC-peptide binding interactions
CN109476727A (zh) * 2016-04-27 2019-03-15 大学健康网络 肽-hla复合物及产生其的方法
WO2019126818A1 (en) * 2017-12-23 2019-06-27 Rubius Therapeutics, Inc. Artificial antigen presenting cells and methods of use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KENJI SUGATA ET AL.: "affinity-mutured HLA CLAA II DIMERS FOR robust staining of antigen-specific CD4+ Tcell", 《NATURE BIOTECHONLOGY》, vol. 108, no. 38, 31 August 2021 (2021-08-31), pages 958 - 973 *
XIN XIANG WANG ET AL.: "affinity maturation of human CD4 by yeast surface display and crystal strucuture of a CD4-HLA-DR1 Complex", 《PNAS》, vol. 108, no. 38, 31 December 2011 (2011-12-31), pages 15960 - 15965, XP055789365, DOI: 10.1073/pnas.1109438108 *
冯石磊;胡墅;刘兵;刘伟;: "抗原肽与MHC分子相互作用QM/MM分子动力学模拟研究", 化学学报, no. 09, 15 September 2013 (2013-09-15), pages 123 - 130 *

Also Published As

Publication number Publication date
WO2021019473A1 (en) 2021-02-04
IL290223A (en) 2022-03-01
EP4004034A1 (en) 2022-06-01
KR20220052943A (ko) 2022-04-28
JP7811540B2 (ja) 2026-02-05
TW202116797A (zh) 2021-05-01
CA3146292A1 (en) 2021-02-04
EP4004034A4 (en) 2023-11-15
US12590139B2 (en) 2026-03-31
JP2022542447A (ja) 2022-10-03
AU2020322246A1 (en) 2022-03-03
MX2022001210A (es) 2022-05-03
BR112022001710A2 (pt) 2022-06-21
US20220275051A1 (en) 2022-09-01

Similar Documents

Publication Publication Date Title
JP7811541B2 (ja) Ｍｈｃクラスｉｉ分子及びその使用方法
CN114761802B (zh) 鉴定t细胞受体的方法
JP7811540B2 (ja) Ｍｈｃクラスｉｉ分子及びその使用方法
JP7815101B2 (ja) Ｍｈｃクラスｉｉ分子及びその使用方法
CN114450414A (zh) T细胞受体及其使用方法
CN114364806A (zh) T细胞受体及其使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination